Evidence map›Paper›PMID 29967379›Full record

ArticleLeukemia2019

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Brian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, T Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, Hongwei Wang, Pingping Qu, Antje Hoering and 29 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07045168 (Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study), which is not on this map. Cited by 280 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
280citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07045168 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study

TypeobservationalSponsorFengYan JinRan2025 to 2029Enrolled200ConditionsMultiple MyelomaArmsrisk-scoring model
3 · Its place in the literature

Who cites it

280 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. iScience · 2026
    Article
  19. Article
  20. Article

220 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors.

Brian A WalkerMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID http://orcid.org/0000-0002-8615-6254
Konstantinos MavrommatisCelgene Corporation, San Francisco, CA, USA.
Christopher P WardellMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
T Cody AshbyMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Michael BauerMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID http://orcid.org/0000-0003-2498-7295
Faith DaviesMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Adam RosenthalCancer Research and Biostatistics, Seattle, WA, USA.
Hongwei WangCancer Research and Biostatistics, Seattle, WA, USA.
Pingping QuCancer Research and Biostatistics, Seattle, WA, USA.
Antje HoeringCancer Research and Biostatistics, Seattle, WA, USA.
Mehmet SamurDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Fadi TowficCelgene Corporation, Summit, NJ, USA.
Maria OrtizCelgene Institute of Translational Research Europe, Sevilla, Spain.
Erin FlyntCelgene Corporation, Summit, NJ, USA.
Zhinuan YuCelgene Corporation, Summit, NJ, USA.
Zhihong YangCelgene Corporation, Summit, NJ, USA.
Dan RozelleRancho BioSciences, San Diego, CA, USA.
John ObenauerRancho BioSciences, San Diego, CA, USA.
Matthew TrotterCelgene Institute of Translational Research Europe, Sevilla, Spain.
Daniel AuclairMultiple Myeloma Research Foundation, Norwalk, CT, USA.
Jonathan KeatsTranslational Genomics Research Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0003-4375-7399
Niccolo BolliUniversity of Milan, Milano, Italy.
Mariateresa FulcinitiDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Raphael SzalatDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Phillipe MoreauUniversity of Nantes, Nantes, France.
Brian DurieCedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
A Keith StewartDepartment of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Hartmut GoldschmidtDepartment of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
Marc S RaabDepartment of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
Hermann EinseleDepartment of Internal Medicine II, Wurzburg University, Wurzburg, Germany.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Jesus San MiguelClinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
Sagar LonialWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Graham H JacksonDepartment of Haematology, Newcastle University, Newcastle, UK.
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Herve Avet-LoiseauCentre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale, U1037, Toulouse, France.
Nikhil MunshiDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Anjan ThakurtaCelgene Corporation, Summit, NJ, USA.
Gareth MorganMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. GJMorgan@uams.edu.

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
6 · The paper itself

Abstract

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R

Indexed as

Chromosome AberrationsGenome, HumanBiomarkers, TumorGenomicsHigh-Throughput Nucleotide SequencingHumansMultiple MyelomaPrognosisRisk FactorsSurvival RateBiomarkers, Tumor

Identifiers

PMID29967379
PMCPMC6326953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.